AUDIENCED

SUCCESS IN WA PILOT TO OBSERVE BABIES SHOWING DELAYS IN SOCIAL INTERACTION & COMMUNICATION DEVELOPMENT World-first program for babies delivered in partnership between the NDIA, The Kids and WA Health Services SEGMENT Filmed in Subiaco, Western Australia | January 2025 INTERVIEWS  Gemma Upson,  General Manager, CliniKids and Inklings The Kids Research Institute Australia Lindy Henry, Child Health Nurse and Inklings Practitioner CliniKids at The Kids Research Institute Australia Professor Andrew Whitehouse, Angela Wright Bennett Professor of Autism Research,  The Kids Research Institute Australia Inklings Program – led by The Kids Research Institute Australia – is a program for babies aged 6-18 months whose communications skills are developing differently to expected milestones. In early 2025 it has completed the first year of a pilot program. At the time of filming (Nov 2024), Inklings has received more then 300 enquiries across WA and started to deliver services to 160 children, with almost 60 who have completed the program. The world-first program for babies with delays in their social and communication skills was funded and launched in Western Australia in early 2024 in partnership with the National Disability Insurance Agency (NDIA), The Kids Research Institute Australia, Child and Adolescent Health Service (CAHS) and WA Country Health Service. The Inklings Program builds on landmark research conducted by The Kids Research Institute Australia, The University of Manchester, La Trobe University and CAHS, which found improvements in parent-child interactions and children’s language skills. Inklings was launched in February 2024 by the Minister for the NDIS and Government Services Bill Shorten and Western Australian Health Minister Amber-Jade Sanderson, Department of Health (WA Health). And in November 2024, the program launched in regional and remote Western Australia, with two new delivery partners joining the Inklings Program. Caregivers who live in WA can either be referred by a health professional or enquire direct to Inklings to see if they are eligible to participate. Australian Health Journal spoke with the management and operational team supporting the program about it’s journey and success to date, including the upcoming South Australian implementation of the program. Produced & published by AUDIENCED Get your interviews captured across Australia https://lnkd.in/gXDkJnad

STEM CELLS USED FOR AGE-RELATED MACULAR DEGENERATION Dr. Jenna Hall Senior Research Associate University of Melbourne, Victoria, Australia RESEARCHER PROFILE  Filmed in Melbourne, Australia | January 2025 Dr. Jenna Hall is a passionate and accomplished biologist with expertise in induced pluripotent stem cell (iPSC) culture, disease modelling, and high-throughput automated systems. She recently earned her PhD from the University of Melbourne, where her research focused on using iPSC-derived retinal pigment epithelium (RPE) cells to study age-related macular degeneration. Dr Hall’s technical skillset spans manual and automated cell reprogramming and differentiation, quantitative microscopy-based phenotyping, and large scale -omics analysis. Dr Hall was awarded a highly competitive and sought after Australian Research Council ARC Centre for Personalised Therapeutics Technologies (ARC CPTT) scholarship which, in addition to funding her PhD, included an industry internship with a leading life sciences consultancy firm. Her internship with Biointelect Pty Ltd allowed her to contribute to strategic projects addressing key challenges in Australia’s biotechnology ecosystem. Her white papers on the country’s vaccine and drug value chain, as well as anti-obesity medication, demonstrated her ability to combine scientific knowledge with commercial insights to influence policy and improve pandemic preparedness. Dr Hall has over four years of industry experience, including her time at the The New York Stem Cell Foundation Research Institute, where she collaborated with engineers and data scientists to develop scalable workflows for cell reprogramming, downstream differentiation, and automated maintenance. For her next career step, Dr Hall is hoping to secure a role in a fertility research lab. SEE OTHER RESEARCHER PROFILES Bench Side Story www.benchsidestory.com Produced & published by AUDIENCED Get your interviews captured across Australia https://lnkd.in/gXDkJnad

INTEGRATING ORAL HEALTH CARE ACROSS NON-DENTAL PROFESSIONALS: Part 1: How oral health and cardiovascular health, diabetes and cognitive decline are related  Associate Professor Rachel Martin, Adjunct Associate Professor, University of Melbourne & Western Sydney University & Director, Australian Network for the Integration of Oral Health (NIOH) & Director, Australian Dental Research Foundation Ltd  Dr Ajesh George, Professor of Interprofessional Oral Health, School of Nursing and Midwifery, Western Sydney University & Co-Founder & Director, Australian Centre for Integration of Oral Health - ACIOH SEGMENT  Filmed in Melbourne & Liverpool, NSW | January 2025 Poor oral health can contribute to or exacerbate several systemic health conditions due to the close connection between oral bacteria, inflammation, and systemic processes. These conditions include cardiovascular health, diabetes, respiratory health, cognitive health, pregnancy and birth outcomes. The Australian Network for the Integration of Oral Health (NIOH) was founded in 2017 to promote and drive the alignment and integration of oral and general health systems. The mission of NIOH is to promote collaborative practice among various health professionals, enhancing access to oral health services and encouraging early preventive care. NIOH has over 120 members across universities, government agencies, not-for-profits, consumer groups, and industry within Australia. Australian Health Journal spoke to Associate Professor Rachel Martin, Director at NIOH about the oral health being intricately linked to overall health, particularly concerning two prevalent diseases: periodontal disease and dental caries, which often go untreated. Assoc Prof Martin, talks about primary healthcare practitioners playing a vital role in early intervention by proactively asking patients about symptoms such as loose teeth and bleeding gums. She comments on AIHW statistics on Australians hospitalised despite potentially preventable oral conditions, underscoring the need for timely care. The Australian Centre for Integration of Oral Health (ACIOH), is the research arm of NIOH. Dr Ajesh George as Co-Founder & Director, of ACIOH spoke to Australian Health Journal about the opportunities that clinical professionals, in dental health care and general health care can play in integrated models of health care and on prevention, early intervention to reduce the burden of disease in Australia. COMING SOON, Part 2 AHJ case study into the implementation and translation Midwifery Initiated Oral Health (MIOH), a Victorian program through Dental Health Services Victoria (DHSV) that equips midwives with the skills and confidence to include oral health in antenatal care. The MIOH program is also offered as continuing professional development (CPD) program for midwives through Australian College of Midwives (ACM). Produced & published by AUDIENCED Get your interviews captured across Australia https://lnkd.in/gXDkJnad

UNNECESSARY TESTS AND TREATMENTS IN LOW VALUE CRITICAL CARE Dr Gerben Keijzers Senior Staff Specialist Emergency Physician, Gold Coast Hospital at Department of Health, Queensland &  Adjunct Professor  Griffith University & Bond University Queensland, Australia RESEARCHER PROFILE  Filmed in Southport, Queensland | January 2025 Dr Gerben Keijzers is a Senior Staff Specialist Emergency Physician at the Gold Coast University Hospital Emergency Department. Dr Keijzers balances half of his time between clinical work and academic duties, including teaching medical students and conducting research. His role also include being an honorary professor of emergency medicine at Bond University and is an associate professor at Griffith University. Dr Keijzers completed a master's degree in epidemiology and medical degree in Nijmegen, The Netherlands. He came to Australia in 2002 and completed his Fellowship in Emergency Medicine in 2008. He has a PhD in the quality of trauma care. He works clinically, conducts clinical research and is a clinical supervisor for medical students on emergency medicine rotation. Over the past 15 years, Dr Keijzers has helped create seven research pillars focused on critical care studies, such as sepsis and antimicrobial stewardship. His research focus includes low-value care, which is in the area of unnecessary tests and treatments with minimal benefits. Dr Keijzers has contributed to over 100 publications and more than 20 grant applications. Through his involvement in multi-site collaborative research projects, he encourages critical thinking and curiosity among clinical staff, striving to enhance both patient care and the efficiency of healthcare resources. He is the former chair of the Queensland Emergency Research Collaborative, a member of the Clinical Trials Group of the Australasian College for Emergency Medicine , a member of the Research Advisory Committee for the Emergency Care Institute and is section editor for the peer-reviewed journal Emergency Medicine Australasia. Note: Narrative adapted from The University of Queensland website and interview SEE OTHER RESEARCHER PROFILES Bench Side Story www.benchsidestory.com Produced and published by AUDIENCED Tap into our rolling national production tour to get your own filmed interviews for your channels or your professional profile. Up to 80% in savings (conditions apply) Contact us here https://lnkd.in/gqyx7nfy 

RADIATION THERAPY TECHNIQUES AND COMBINATION TREATMENTS FOR SARCOMA Professor Angela Hong, Director and  co-Chair of Scientific Advisory Committee, Australia and New Zealand Sarcoma Association (ANZSA) RESEARCHER PROFILE   Filmed Sydney, Australia | January 2025 Professor Angela Hong MBBS, MMed, PhD, FRANZCR is a Professor at Sydney Medical School of the University of Sydney. She is a radiation oncologist and has been a member of the Multidisciplinary Bone and Soft Tissue Tumour Clinic at Royal Prince Alfred Hospital/Chris O'Brien Lifehouse for the past 15 years. She is also the Director and co-chair of the Scientific Advisory Committee for the Australia and New Zealand Sarcoma Association (ANZSA), a non-profit organisation aimed at enhancing treatment outcomes for sarcoma patients across Australia and New Zealand. As a radiation oncologist located in Sydney, Australia, Professor Hong is focused on treating patients with bone and soft tissue sarcoma. And as a clinician scientist, her research focuses on developing innovative radiation therapy technique and combination treatments to improve the outcome for patients with sarcoma. After earning her medical degree from the University of Sydney, Angela undertook an 18-month fellowship in the United States to gain additional experience before returning to Sydney to start her formal training in radiation oncology. She later completed her PhD, concentrating on radiosensitivity in skin cancer sarcoma. Professor Hong believes in a multidisciplinary approach to managing sarcoma, given its rarity and the complexities involved in diagnosis and treatment. She is actively involved in clinical research and recently contributed to an international trial led by SARC-Sarcoma Alliance for Research through Collaboration in the United States and the Australia and New Zealand Sarcoma Association (ANZSA) in Australia. The trial examined the advantages of including immunotherapy in the treatment regimen for high-risk soft tissue sarcoma, resulting in a notable improvement in two-year disease-free survival rates. SEE OTHER RESEARCHER PROFILES Bench Side Story www.benchsidestory.com

CORNEAL AND OCULAR SURFACE IMMUNOLOGY AND REGENERATION Associate Professor Holly Chinnery, Inaugural Ian Constable Research Fellow, Lions Eye Institute, UWA Optometry at The University of Western Australia RESEARCHER PROFILE   Filmed in Perth, Western Australia | November 2024 Associate Professor Holly Chinnery is a teaching and research academic in the field of corneal and ocular immunology who has spent her career teaching anatomy and immunology to Optometry students at the University of Melbourne and now at UWA, while also leading a Corneal and Ocular Immunology Research team. Career highlights include: - Leading a team of students and early career staff over the past 15 years working on corneal and retinal immunology, a co-leading the FrontTear Research Centre - University of Melbourne with Professor Laura Downie at the University of Melbourne https://www.fronttear.au/ - Receiving NH&MRC Ideas and ARC Discovery Grant funding - Speaking invitations at Oxford University, University of Birmingham and the Association for Research in Vision and Ophthalmology; and recent publications in PNAS and Nature Reviews Immunology. Assoc Professor Chinnery’s career in ocular immunology began with a focus on animal models; however, it has recently transitioned into clinical imaging studies involving human research participants. The ability to visualise the immune system and sensory nerves in the human cornea represents a significant advantage in corneal immunology and neuroimmunology research. This advancement is made possible through a methodology called Functional In Vivo Confocal Microscopy (Fun-IVCM), which enables the observation of immune cell dynamics in the living human eye. Utilising this technology led to a breakthrough in the field of ocular immunology, culminating in a report published in PNAS, a highly prestigious journal, regarding the presence of T cells in the healthy human cornea https://lnkd.in/gFji5tTR. This finding challenges existing dogmas and is poised to reshape the field of corneal immunology, prompting a reconsideration of previously held beliefs about how the cornea manages inflammation and immune protection, with direct implications for healthy vision. For the first time, a variety of immune cells can be visualised in the living human cornea, generating a wealth of new questions about immunology, cell biology, and the effects that diseases outside the eye have on immune cells at the eye's surface. In her recent appointment at the Lions Eye Institute, Assoc Professor Chinnery aims to establish and support a team of researchers focused on corneal and ocular surface regeneration, which is one of the key research priorities of the Institute. SEE OTHER RESEARCHER PROFILES Bench Side Story www.benchsidestory.com 

GENOME WIDE ASSOCIATION STUDIES FOR BREAST CANCER Distinguished Scientist Professor Georgia Chenevix-Trench Head of Cancer Genetics QIMR Berghofer Medical Research Institute RESEARCHER PROFILE Filmed October 2024 | Brisbane, Queensland, Australia Professor Georgia Chenevix-Trench is a Distinguished Scientist at QIMR-Berghofer in Brisbane, Australia. She has had a long term interest in inherited cancer syndromes, identifying the gene for nevoid basal cell carcinoma syndrome back in 1996. Using whole genome sequencing, she identified the gene for Gastric Adenocarcinoma and Proximal Polyposis of the Stomach in 2016. She is the author of more than 500 peer-reviewed papers, and has been instrumental in the collection of public resources such as kConFab, the Australian consortium for research into familial breast cancer. She has used kConFab extensively for other research projects over the last 25 years, including for analysis of unclassified variants in BRCA1/2 and to show that mutations in the ATM gene confer moderate risks for breast cancer. She is the founder and leader of CIMBA, the Consortium of Investigators of Modifiers of BRCA1/2, established in 2005 with the aim of providing sufficient sample sizes to allow large scale studies to identify and evaluate reliably the effects of genetic modifiers. She is also a founding member of the Breast and Ovarian Cancer Association Consortia, which have identified over 250 novel breast and ovarian cancer susceptibility loci since the advent of genome-wide association studies, many of which have been shown by CIMBA to also modify cancer risk for BRCA1/2 carriers. The major focus of her current research is to determine the function of variants associated with breast cancer risk, using CRISPR screens to identify target genes with opportunities for drug repositioning. She was elected to the Australian Academy of Science in 2014, for her work on the genetics of breast, ovarian and other cancers, was awarded the Suzanne Cory Medal and Lecture by the Australian Academy of Science, and the GSK Award for Research Excellence, in 2022. Her research has included funding from Australia's National Health and Medical Research Council (NHMRC), United States Department of Defense, National Breast Cancer Foundation & the Susan Komen Foundation. SEE OTHER RESEARCHER PROFILES Bench Side Story www.benchsidestory.com

NATIONAL BREAST CANCER FOUNDATION (NBCF) OUTLINES PINK HORIZON RESEARCH STRATEGY AT BREAST CANCER FORUM Breast Cancer Awareness Month demonstrates integral role of NBCF in research and clinical support Filmed in Brisbane, Queensland | November 2024 Associate Professor Cleola Anderiesz, Chief Executive Officer of the National Breast Cancer Foundation, leads an organisation dedicated to funding world-class breast cancer research in Australia. The Foundation has a bold vision of achieving zero deaths from breast cancer. Every October, during Breast Cancer Awareness Month, the foundation uses this time to raise awareness about breast cancer and its impact in Australia. It also emphasises the critical need for funding breast cancer research to improve outcomes. The National Breast Cancer Foundation collaborates with researchers, providing essential funding while also engaging them, clinicians, and consumers to establish research priorities. Australian Health Journal met with Assoc Prof Anderiesz to hear of the new 5 year Pink Horizon research strategy. Those with lived experience of breast cancer, along with researchers, clinicians, and other funding organisations, have contributed to the development of the foundation’s new five-year Pink Horizon research strategy. This ambitious plan aims to invest $125 million to accelerate research efforts towards the vision of ending deaths from breast cancer. Recently, Assoc Professor Anderiesz presented at the Public Breast Cancer Research Forum hosted by The University of Queensland and the Translational Research Institute Australia, where she highlighted the accomplishments of the National Breast Cancer Foundation over the past 30 years. During this time, the Foundation has invested over $200 million into more than 600 research projects across Australia, supporting 1,800 researchers at 120 institutes to advance impactful breast cancer research. Professor Anderiesz believes it is essential for all members of the breast cancer community to consistently seek opportunities to raise awareness about the disease's impact. This awareness should extend beyond October and include efforts to inform primary care physicians and specialists. Additionally, there is a need to promote groundbreaking research and advocate for changes in policy and care to improve outcomes for individuals affected by breast cancer.

FORUM FOSTERS DIALOGUE BETWEEN BREAST CANCER LIVED EXPERIENCE ADVOCATES, RESEARCHERS AND CLINICIANS Organised by the The University of Queensland and Translational Research Institute Australia In October 2024, the Frazier Institute hosted an event dedicated to breast cancer advocacy and research, supported by TRI (Translational Research Institute), National Breast Cancer Foundation, PA Research Foundation, Health Translation Queensland, QUT (Queensland University of Technology) and The University of Queensland Faculty of Medicine/Frazer Institute. The key aim of the event co-organised by Associate Professor Joy Wolfram, PhD, Group Leader, Australian Institute for Bioengineering and Nanotechnology AIBN & School of Chemical Engineering, The University of Queensland was to foster dialogue between breast cancer lived experience advocates (consumers), researchers, and clinicians. Co-organiser Associate Professor Fernando Guimaraes, Group Leader, Principal Research Fellow, Frazer Institute, The University of Queensland and UQ Health, Medicine and Behavioural Sciences spoke to Australian Health Journal about the need to host the event and regularly engage with consumers. Jo Maxwell, Principal Project Officer, Consumer and Community Involvement in Research Strategy and Support at The University of Queensland also spoke about the standards for consumer participation and collaboration adopted from the International Association for Public Participation (IAP2) Australasia (IAP2). “IAP2 guides the researcher to structure consumer involvement all through the different stages of their research”, says Maxwell. Associate Professor Cleola Anderiesz, Chief Executive Officer National Breast Cancer Foundation presented at the Forum and spoke to Australian Health Journal on the impact of engagement when communities, researchers and clinicians come together to hear about the latest research and discuss a future of better breast cancer care and outcomes. The day long event was enlightening and impactful. The forum in Brisbane included a workshop focused on creating international connections between breast cancer consumers in Australia and the United States, with insights from leading breast cancer oncologists, clinicians, consumers, researchers, and community.